Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of topical diacerein 1% ointment in epidermolysis bullosa simplex
MOH_2018-01-17_002009Phase 2Not yet recruiting
- Sponsor
- Castle Creek Biosciences
- Start
- Jan 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diacerein in epidermolysis bullosa simplex (EBS), sponsored by Castle Creek Biosciences. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on MOH_2018-01-17_002009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-17_002009.